CASI Pharmeceuticals

Clinical

Clinical Trials

Clinical Trials Currently Enrolling

Please contact the individual trial centers listed below for enrollment information. You may also click on the clinicaltrials.gov link for specific trial information.

Product Candidate Location Principal Investigator Indication Phase Contact
ENMD-2076 Princess Margaret Hospital Malcolm Moore, MD Albiruni R.A. Razak, MD Advanced/Metastatic Soft Tissue Sarcoma II Mandeep Grewal (416) 946-4501 ext. 3039
ENMD-2076 Multi-center Amit M. Oza, MD Ovarian Clear Cell Carcinoma II Stephanie Capobianco, B.Sc.,416-946-4501 ext. 5185
ENMD-2076 MSKCC Ghassan Abou-Alfa, MD Fibrolamellar Carcinoma II David Markowitz davidm@casipharmaceuticals.com
ENMD-2076 University of CO, Denver Stephen Leong, MD Fibrolamellar Carcinoma II David Markowitz davidm@casipharmaceuticals.com
ENMD-2076 Dana-Farber Cancer Inst. Rober Mayer, MD Fibrolamellar Carcinoma II David Markowitz davidm@casipharmaceuticals.com
ENMD-2076 University of CA, San Francisco John Gordan, MD Fibrolamellar Carcinoma II David Markowitz davidm@casipharmaceuticals.com
ENMD-2076 UT, Southwestern Muhmmad Beg, MD Fibrolamellar Carcinoma II David Markowitz davidm@casipharmaceuticals.com
ENMD-2076 Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China XU, Binghe, MD TNBC II Rong Chen, MD. rongc@casipharmaceuticals.com.cn

Ongoing Trials, Enrollment Closed

Product Candidate Location Principal Investigator Indication Phase
ENMD-2076 University of Colorado Cancer Center Jennifer Diamond, MD Triple-Negative Breast Cancer II Tiffany Colvin (720) 848-0664
ENMD-2076 Indiana University Melvin and Bren Simon Cancer Center Kathy Miller, MD Triple-Negative Breast Cancer II Kathy Miller, MD (317) 944-1690
ENMD-2076 University of Colorado and Dana-Farber Cancer Institute Dr. Wells Messersmith & Dr. Geoffrey Shaprio Advanced Cancers I

* NCI-sponsored trial. CASI Pharmaceuticals provided only the study drug for this trial.
** NCI-sponsored trial. CASI Pharmaceuticals provided only the study drug for this trial.

About Us

A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.

Learn More

In the News

CASI's turnaround turns eastward; firm seeks to be Celgene of China

Read Article →

Poster

Antitumor activity, safety and predictive biomarker results of ENMD-2076 administered to patients with recurrent ovarian clear cell carcinoma (OCCC): A trial of the Princess Margaret Phase II Consortium

Download →

Poster

Senescence as a Mechanism of Resistance to Aurora Kinase Inhibition with ENMD-2076 in p53 mutated Triple-Negative Breast Cancer (TNBC) Models

Download →